Cargando…

Cost–utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer

BACKGROUND: Apixaban (2.5 mg) taken twice daily has been shown to substantially reduce the risk of venous thromboembolism (VTE) compared with placebo for the primary thromboprophylaxis of ambulatory patients with cancer who are starting chemotherapy and are at intermediate-to-high risk of VTE. We ai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimpton, Miriam, Kumar, Srishti, Wells, Philip S., Coyle, Doug, Carrier, Marc, Thavorn, Kednapa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	CMA Joule Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568073/ https://www.ncbi.nlm.nih.gov/pubmed/35040802 http://dx.doi.org/10.1503/cmaj.210523

Ejemplares similares

Cost-effectiveness of integrated disease management for high risk, exacerbation prone, patients with chronic obstructive pulmonary disease in a primary care setting
por: Scarffe, Andrew D., et al.
Publicado: (2022)

The Health System Costs of Potentially Inappropriate Prescribing: A Population-Based, Retrospective Cohort Study Using Linked Health Administrative Databases in Ontario, Canada
por: Black, Cody D., et al.
Publicado: (2019)

Thromboprophylaxis with apixaban and the risk of pulmonary embolism in patients undergoing knee replacement surgery
por: Aryal, Madan Raj, et al.
Publicado: (2015)

Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand?
por: Mulder, Frits I., et al.
Publicado: (2020)

Primary Bankart Repair Versus Arthroscopic Anatomic Glenoid Reconstruction in Patients with Subcritical Bone Loss: A Cost-Utility Analysis
por: Ali, Zakariya S., et al.
Publicado: (2021)

Protocol for a modelling study to assess the clinical and cost-effectiveness of indefinite anticoagulant therapy for first unprovoked venous thromboembolism
por: Khan, Faizan, et al.
Publicado: (2023)

Thromboprophylaxis With Apixaban in Patients Undergoing Major Orthopedic Surgery: Meta-Analysis and Trial-Sequential Analysis
por: Caldeira, Daniel, et al.
Publicado: (2017)

Health system costs of potentially inappropriate prescribing in Ontario, Canada: a protocol for a population-based cohort study
por: Black, Cody D, et al.
Publicado: (2018)

Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis
por: Yu, Zhi, et al.
Publicado: (2018)

Cost–Utility Analysis of Radiation Treatment Modalities for Intermediate-Risk Prostate Cancer
por: Alyamani, Najlaa, et al.
Publicado: (2021)

Index hospital cost of adverse events following thoracic surgery: a systematic review of economic literature
por: Jones, Daniel, et al.
Publicado: (2023)

Audit feedback interventions to address high-risk prescriptions in long-term care homes: a costing study and return on investment analysis
por: Thavorn, Kednapa, et al.
Publicado: (2021)

Costs of Next-Generation Sequencing Assays in Non-Small Cell Lung Cancer: A Micro-Costing Study
por: Kumar, Srishti, et al.
Publicado: (2022)

Prevention of venous thromboembolism in ambulatory patients with cancer
por: Khorana, Alok A, et al.
Publicado: (2020)

COVID-19 Pandemic: Did Strict Mobility Restrictions Save Lives and Healthcare Costs in Maharashtra, India?
por: Ambade, Preshit Nemdas, et al.
Publicado: (2023)

Increased dose primary thromboprophylaxis in ambulatory patients with advanced pancreatic ductal adenocarcinoma, a single centre cohort study
por: Maraveyas, Anthony, et al.
Publicado: (2020)

Thromboprophylaxis in Patients With COVID-19: A Brief Update to the CHEST Guideline and Expert Panel Report
por: Moores, Lisa K., et al.
Publicado: (2022)

Primary Thromboprophylaxis in Ambulatory Pancreatic Cancer Patients Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Frere, Corinne, et al.
Publicado: (2020)

Lifetime patient outcomes and healthcare utilization for Bronchopulmonary dysplasia (BPD) and extreme preterm infants: a microsimulation study
por: van Katwyk, Sasha, et al.
Publicado: (2020)

Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes
por: Hammami, Rania, et al.
Publicado: (2022)

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons
por: Gómez-Outes, Antonio, et al.
Publicado: (2012)

Cost-effectiveness of mechanical thromboprophylaxis for cesarean deliveries in Brazil
por: Veloz, Alex, et al.
Publicado: (2023)

An Electronic Patient-Reported Outcomes Tool for Older Adults With Complex Chronic Conditions: Cost-Utility Analysis
por: Miranda, Rafael N, et al.
Publicado: (2022)

Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand
por: Permsuwan, Unchalee, et al.
Publicado: (2016)

Cost analysis of the very elderly admitted to intensive care units
por: Chin-Yee, Nicolas, et al.
Publicado: (2017)

What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial
por: Sayar, Zara, et al.
Publicado: (2019)

Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial
por: Barco, Stefano, et al.
Publicado: (2020)

P1646: A SYSTEMATIC REVIEW AND META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS ON PRIMARY AMBULATORY THROMBOPROPHYLAXIS (PATP) IN PATIENTS WITH LYMPHOMA RECEIVING CHEMOTHERAPY
por: Htut, Thura, et al.
Publicado: (2023)

A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients post major abdominal surgery
por: Al Rawahi, Bader, et al.
Publicado: (2017)

Determining the hospital cost of anterior epistaxis treatment modalities at a Canadian tertiary care centre
por: Nithianandan, Harrish, et al.
Publicado: (2019)

Preparation of Apixaban Solid Dispersion for the Enhancement of Apixaban Solubility and Permeability
por: Lee, Juseung, et al.
Publicado: (2023)

Dizziness at a Canadian tertiary care hospital: a cost-of-illness study
por: Le, Andre, et al.
Publicado: (2019)

Cost-Effectiveness of Colchicine for Recurrent Cardiovascular Events
por: Boczar, Kevin E., et al.
Publicado: (2023)

A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients with active cancer hospitalized with an acute medical illness
por: Moretto, Patricia, et al.
Publicado: (2015)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
por: Amin, Alpesh, et al.
Publicado: (2023)

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence
por: Zalpour, Ali, et al.
Publicado: (2014)

Factors contributing to high-cost hospital care for patients with COPD
por: Mulpuru, Sunita, et al.
Publicado: (2017)

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
por: Lee, Soyon, et al.
Publicado: (2012)

Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria
por: Aoudia, Yazid, et al.
Publicado: (2017)

Cost-effectiveness analysis of the SMART quit clinic program in smokers with cardiovascular disease in Thailand
por: Grant, Alyssa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h4esv1bnro9f13ffj40h1s64cl